JTJantima Tanboon

Jantima Tanboon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jantima Tanboon has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Ichizo Nishino

    Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan

    4 shared publications
  • Ichizo Nishino

    Department of Neuromuscular Research National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP) Tokyo Japan

    3 shared publications
  • Michio Inoue

    Department of Neuromuscular Research National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP) Tokyo Japan

    3 shared publications
  • Manabu Fujimoto

    Department of Dermatology, Faculty of Medicine University of Tsukuba Tsukuba Ibaraki Japan

    2 shared publications
  • Shigeaki Suzuki

    Department of Neurology Keio University School of Medicine Tokyo Japan

    2 shared publications
  • Shinichiro Hayashi

    Department of Neuromuscular Research, National Institute of Neuroscience National Center of Neurology and Psychiatry (NCNP) Kodaira Tokyo Japan

    2 shared publications

Latest Publications

  • Open Access

    Exploiting nanopore sequencing for characterization and grading of IDH‐mutant gliomas

    by Thidathip Wongsurawat, Piroon Jenjaroenpun, Panatna Anekwiang, Tantip Arigul, Wichayapat Thongrattana, Azemat Jamshidi‐Parsian, Gunnar Boysen, Prapat Suriyaphol, Bhoom Suktitipat, Prajak Srirabheebhat, et al.

    The 2021 WHO Classification of Central Nervous System Tumors recommended evaluation of cyclin‐dependent kinase inhibitor 2A/B (CDKN2A/B) deletion in addition to codeletion of 1p/19q to characterize IDH‐mutant gliomas. Here, we demonstrated the use of a nanopore‐based copy‐number variation sequencing (nCNV‐seq) approach to simultaneously identify deletions of CDKN2A/B and 1p/19q. The nCNV‐seq approach was initially evaluated on three distinct glioma cell lines and then applied to 19 IDH‐mutant gliomas (8 astrocytomas and 11 oligodendrogliomas) from patients. The whole‐arm 1p/19q codeletion was detected in all oligodendrogliomas with high concordance among nCNV‐seq, FISH, DNA methylation profiling, and whole‐genome sequencing. For the CDKN2A/B deletion, nCNV‐seq detected the loss in both astrocytoma and oligodendroglioma, with strong correlation with the CNV profiles derived from whole‐genome sequencing (Pearson correlation (r) = 0.95, P < 2.2 × 10−16 to r = 0.99, P < 2.2 × 10−16) and methylome profiling. Furthermore, nCNV‐seq can differentiate between homozygous and hemizygous deletions of CDKN2A/B. Taken together, nCNV‐seq holds promise as a new, alternative approach for a rapid and simultaneous detection of the molecular signatures of IDH‐mutant gliomas without capital expenditure for a sequencer.


  • Open Access

    Editorial: Inflammatory muscle diseases: an update

    by Jantima Tanboon, Merrilee Needham, Tahseen Mozaffar, Werner Stenzel, Ichizo Nishino

    Editorial: Inflammatory muscle diseases: an update


  • Open Access

    A 53‐year‐old man with a 16‐year history of asymmetrical proximal muscle weakness, facial muscle weakness, and scapular winging

    by Jantima Tanboon, Rasha El Sherif, Michio Inoue, Mariko Okubo, Edoardo Malfatti, Ichizo Nishino


  • Open Access

    Muscle pathology of antisynthetase syndrome according to antibody subtypes

    by Jantima Tanboon, Michio Inoue, Shinya Hirakawa, Hisateru Tachimori, Shinichiro Hayashi, Satoru Noguchi, Naoko Okiyama, Manabu Fujimoto, Shigeaki Suzuki, Ichizo Nishino

    Identification of antisynthetase syndrome (ASS) could be challenging due to inaccessibility and technical difficulty of the serology test for the less common non‐Jo‐1 antibodies. This study aimed to describe ASS antibody‐specific myopathology and evaluate the diagnostic utility of myofiber HLA‐DR expression. We reviewed 212 ASS muscle biopsies and compared myopathologic features among subtypes. Additionally, we compared their HLA‐DR staining pattern with 602 non‐ASS myositis and 140 genetically confirmed myopathies known to have an inflammatory component. We used t‐test and Fisher's exact for comparisons and used sensitivity, specificity, positive and negative predictive values to assess the utility of HLA‐DR expression for ASS diagnosis. RNAseq performed from a subset of myositis cases and histologically normal muscle biopsies was used to evaluate interferon (IFN)‐signaling pathway‐related genes. Anti‐OJ ASS showed prominent myopathology with higher scores in muscle fiber (4.6 ± 2.0 vs. 2.8 ± 1.8, p = 0.001) and inflammatory domains (6.8 ± 3.2 vs. 4.5 ± 2.9, p = 0.006) than non‐OJ ASS. HLA‐DR expression and IFN‐γ‐related genes upregulation were prominent in ASS and inclusion body myositis (IBM). When dermatomyositis and IBM were excluded, HLA‐DR expression was 95.4% specific and 61.2% sensitive for ASS with a positive predictive value of 85.9% and a negative predictive value of 84.2%; perifascicular HLA‐DR pattern is common in anti‐Jo‐1 ASS than non‐Jo‐1 ASS (63.1% vs. 5.1%, p < 0.0001). In the appropriate clinicopathological context, myofiber HLA‐DR expression help support ASS diagnosis. The presence of HLA‐DR expression suggests involvement of IFN‐γ in the pathogenesis of ASS, though the detailed mechanisms have yet to be elucidated.


  • Update on dermatomyositis

    by Jantima Tanboon, Ichizo Nishino

    Purpose of review: This review summarizes and comments on current knowledge in dermatomyositis. Recent findings: The 2018 European Neuromuscular Centre classification of dermatomyositis has been challenging by the discovery of clinicopathological features associated with dermatomyositis-specific antibody (DMSA) that were not incorporated in the original criteria. These features include but may not be limited to the presence of perifascicular necrosis in anti-Mi-2 dermatomyositis; presence of diffuse nonperifascicular sarcoplasmic myxovirus resistance protein A expression in anti-MDA5 dermatomyositis; and dermatomyositis sine dermatitis in anti-NXP-2 dermatomyositis. Variations and subclassifications within the same DMSA subtypes are observed: anti-MDA5 dermatomyositis is clinically subcategorized into good, intermediate, and poor prognostic subgroups; concurrent anti-CCAR1 and anti-TIF1-γ positivity identify anti-TIF1-γ-positive patient with a lower risk for cancer-associated myositis. Owing to distinct IFN1-signaling pathway activation in dermatomyositis, JAK-STAT inhibitor – the pathway-targeted therapy, have been studied with promising results in refractory dermatomyositis and some new-onset dermatomyositis. In addition, the potential serum biomarkers for IFN1 pathway activation are being investigated for their performance in monitoring the disease activity and the efficacy of the treatment. Summary: DMSA, evidence of prominent IFN1 pathway activation, and risk/severity-associated biomarkers would likely play major roles in future dermatomyositis classification, disease monitoring, and treatment decision.


  • Open Access

    Dermatomyositis: Muscle Pathology According to Antibody Subtypes

    by Jantima Tanboon, Michio Inoue, Yoshihiko Saito, Shinichiro Hayashi, Satoru Noguchi, Naoko Okiyama, Manabu Fujimoto, Ichizo Nishino

    Importance: Current pathological criteria of dermatomyositis (DM) do not recognize different features among DM subtypes classified by dermatomyositis-specific antibodies (DMSAs). Objective: To determine whether myopathological features differ among DM subtypes classified by DMSAs and whether the pathological features can be characterized by serologically defined DM subtype. Design: Retrospective review of muscle pathology slides of 256 patients diagnosed with DM from January 2009 to December 2020. Setting: Single center study in a tertiary laboratory for muscle diseases. Participants: A total of 256 patients whose DM diagnosis was pathologically confirmed based on the sarcoplasmic expression of myxovirus resistant protein A (MxA) were included. Of these, 249 patients were positive for one of the 5 DMSAs (seropositive patients, anti-TIF1-γ=87, anti-Mi-2=40, anti-MDA5=29, anti-NXP-2=83, and anti-SAE=10), and 7 were negative for all 5 DMSAs (seronegative patients). Exposure: Histochemical, enzyme histochemical, immunohistochemical staining, and ultrastructural study. Main outcomes and measures: Histological features stratified according to four pathology domains: muscle fiber, inflammatory, vascular, and connective tissue domains, and histological features of interest by histochemistry, enzyme histochemistry, and immunohistochemical study commonly used in the diagnosis of inflammatory myopathy. Results: DMSAs significantly associated with characteristic histochemical and immunohistochemical features were as follows: anti-TIF1-γ with vacuolated/punched out fibers (64.7%, P <.001) and perifascicular enhancement in HLA-ABC (75.9%, P <.001); anti-Mi-2 with prominent muscle fiber damage (score 4.8±2.1, P <.001), inflammatory cell infiltration (score 8.0±3.0, P =.002), perifascicular atrophy (67.5%, P =.02), perifascicular necrosis (52.5%, P <.001), increased perimysium alkaline phosphatase activity (70.0%, P <.001), central necrotic peripheral regenerating fibers (45.0%, P <.001), and sarcolemmal deposition of the membrane attack complex (67.5%, P <.001); anti-MDA5 with scattered/diffuse staining pattern of MxA (65.5%, P <.001) with less muscle pathology and inflammatory features; and anti-NXP2 with microinfarction (26.5%, P <.001); and anti-SAE and seronegative DM with HLA-DR expression (50.0%, P =.02 and 57.1%, P =.02 respectively). Conclusion and relevance: We described an extensive study on serological-pathological correlation of DM primarily using MxA expression as an inclusion criterion. DMSAs was associated with distinctive myopathological features in our studied cohort, suggesting that different pathobiological mechanisms may underscore each subtype. Key points: Question: Are myopathological features different among dermatomyositis (DM) subtypes classified by DM-specific autoantibodies (DMSAs)? If so what are the characteristic features of each subtype? Findings: This study enrolled 256 (249 DMSA-positive and 7 seronegative) patients whose DM diagnosis was made pathologically by confirming the expression of myxovirus resistant protein A in the sarcoplasm of muscle fibers in muscle biopsy samples. The DM subtypes classified by the positive DMSAs were associated with distinctively characteristic pathological features. Meaning: Different pathological features suggest different pathological mechanisms may well underly each DM subtype classified by DMSA.


  • Open Access

    Inflammatory features in sporadic late‐onset nemaline myopathy are independent from monoclonal gammopathy

    by Jantima Tanboon, Akinori Uruha, Yukie Arahata, Carsten Dittmayer, Leonille Schweizer, Hans‐Hilmar Goebel, Ichizo Nishino, Werner Stenzel

    Sporadic late‐onset nemaline myopathy (SLONM) is a rare adult‐onset non‐hereditary disease with subacute proximal muscle and often axial muscle weakness, characterized by the presence of nemaline bodies in skeletal muscle biopsies. Considering its association with concurrent monoclonal gammopathy of undetermined significance (MGUS), the disease is classified into two major subtypes (1) SLONM without MGUS (SLONM‐noMGUS) and (2) with MGUS (SLONM‐MGUS) association. SLONM associated with HIV infection (SLONM‐HIV) is also reported. SLONM‐MGUS has been shown to be associated with poorer prognosis and required aggressive treatment including high‐dose melphalan and autologous stem cell transplantation. The approach is currently debatable as recent reports suggested effectiveness of intravenous immunoglobulin as initial treatment with indifference of overall survival despite the presence of MGUS. Our study aimed to find an underlying basis by review of pathological features in 49 muscle biopsy proven‐SLONM from two large tertiary centers in Japan and Germany (n = 49: SLONM‐noMGUS = 34, SLONM‐MGUS = 13, SLONM‐HIV = 2). We compared pathological findings in SLONM‐noMGUS and SLONM‐MGUS and focused on the presence of any detectable inflammatory features by immunohistochemistry. The clinical and histological features in SLONM‐noMGUS and SLONM‐MGUS were not distinctively different except for more common regenerating fibers (>5% of myofibers) present in SLONM‐MGUS (p < 0.01). HLA‐ABC expression and fine granular p62 were observed in 66.7% and 78.3% of SLONM, respectively. The predominant inflammatory cells were CD68+ cells. The inflammatory cells showed positive correlations with the percentage of nemaline‐containing fibers (p < 0.001). In conclusion, inflammatory features are present although rather mild in SLONM. This finding contributes to the hypothesis of an acquired inflammatory disease pathogenesis and opens the possibility to offer immunotherapy in SLONM with inflammatory features regardless of the monoclonal gammopathy status.


  • Open Access

    A cavernous venous malformation of the orbit mimicking an idiopathic orbital inflammation

    by Niphon Chirapapaisan, Chanon Ngamsombat, Jantima Tanboon, Pornsuk Cheunsuchon, Sugamon Koohasawad

    Orbital cavernous venous malformations (CVMs) are usually slow progressing. Multiple CVMs, bilateral orbital CVMs, and acute presentations are rare. We present a rare, bilateral, orbital CVM with acute painful visual loss in the left eye. The initial clinical presentation mimicked an idiopathic orbital inflammation. Orbital magnetic resonance imaging revealed its rare location at the left orbital apex. Finally, pathology confirmed the presence of an intralesional hemorrhage of a CVM.


  • Concurrent positive anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibody with reducing body myopathy: Possible double trouble

    by Jantima Tanboon, Oranee Sanmaneechai, Sirirat Charuvanij, Tumtip Sangruchi, Angeles S. Galindo-Feria, Ingrid E. Lundberg, Yuko Ohnuki, Takashi Shiina, Shigeaki Suzuki, Ichizo Nishino


  • The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation

    by David P. Kodack, Vasileios Askoxylakis, Gino B. Ferraro, Qing Sheng, Mark Badeaux, Shom Goel, Xiaolong Qi, Ram Shankaraiah, Z. Alexander Cao, Rakesh R. Ramjiawan, et al.

    The brain microenvironment triggers HER3-dependent de novo resistance to therapies targeting PI3K or HER2 in HER2-positive and/or PIK3CA -mutant breast cancer cells.